These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37643716)

  • 1. Analysis of the impact of fatty acid metabolism on immunotherapy for hepatocellular carcinoma.
    Wang J; Jin X
    Ann Hepatol; 2023; 28(6):101148. PubMed ID: 37643716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
    Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
    Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
    Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
    BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatics analysis and experimental verification of the prognostic and biological significance mediated by fatty acid metabolism related genes for hepatocellular carcinoma.
    Zhu XR; Zhu JQ; Chen YF; Liu YY; Lu JJ; Sun J; Peng SQ; Chen MB; Du YP
    Front Oncol; 2022; 12():972744. PubMed ID: 35982956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.
    Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X
    Front Immunol; 2024; 15():1397541. PubMed ID: 38774870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma.
    Hu N; Li H; Tao C; Xiao T; Rong W
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
    Mo Z; Liu D; Rong D; Zhang S
    Front Immunol; 2021; 12():611058. PubMed ID: 33679749
    [No Abstract]   [Full Text] [Related]  

  • 10. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.
    Chen L; Zhou Q; Liu J; Zhang W
    Front Immunol; 2021; 12():759565. PubMed ID: 34777372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
    Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
    Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review.
    Hu B; Lin JZ; Yang XB; Sang XT
    Cell Prolif; 2020 Mar; 53(3):e12772. PubMed ID: 32003505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
    Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
    Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial immunotherapy strategies for hepatocellular carcinoma.
    Tagliamonte M; Petrizzo A; Tornesello ML; Ciliberto G; Buonaguro FM; Buonaguro L
    Curr Opin Immunol; 2016 Apr; 39():103-13. PubMed ID: 26851637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
    Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma.
    Wang N; Tan HY; Lu Y; Chan YT; Wang D; Guo W; Xu Y; Zhang C; Chen F; Tang G; Feng Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):86. PubMed ID: 33633112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.